A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women
Table 1
Clinical and biochemical features of patients treated with denosumab at baseline and at 4 and 12 weeks after denosumab injection.
Parameters
Baseline
4 weeks
12 weeks
14
14
14
Age, years
67.1 ± 11.6
BMI, kg/m2
24.8 ± 3.7
24.5 ± 4.3
24.8 ± 4.1
ns
Bone metabolic parameters
Serum calcium*, mg/dL
9.6 ± 0.6
9.1 ± 0.4
9.0 ± 0.3
0.01
Serum phosphate, mg/dL
3.4 ± 0.3
3.1 ± 0.5*
3.2 ± 0.6
0.02*
Total ALP, UI/L
81.6 ± 26.8
72.7 ± 24.4
53.2 ± 14.1
0.001
PTH, pg/mL
59.1 ± 34.1
89.4 ± 59.6
74.8 ± 36.6
ns
Serum 25OHD**, ng/dL
26.9 ± 6.5
30.6 ± 10.5
34.6 ± 7.7
ns
L1-L4 -score
−3.3 ± 1.5
Neck -score
−2.3 ± 1.0
Femur -score
−2.2 ± 1.0
Glucose metabolic parameters
Serum glucose, mg/dL
91.4 ± 10.1
89.6 ± 14.1
92.1 ± 15.3
ns
Serum insulin, μUI/mL
9.5 ± 6.7
8.5 ± 5.5
10.5 ± 10.1
ns
HOMA-IR°
2.2 ± 1.7
2.0 ± 1.4
2.7 ± 3.1
ns
HbA1c, mmol/mol
37.6 ± 5.4
37.8 ± 4.2
36.4 ± 5.6
0.04
AUC glucose∧, mg/dL*min
2.8 ± 2.8
2.8 ± 2.7
2.7 ± 2.7
ns
Matsuda index
5.3 ± 3.0
5.8 ± 3.2
6.6 ± 4.7
ns
Insulinogenic index
0.9 ± 0.8
0.5 ± 0.4
0.8 ± 0.6
ns
HIRI°°
6.6 ± 6.5
6.4 ± 6.3#
6.6 ± 6.7
0.01#
Albumin-corrected calcium; **25-hydroxyvitamin D; °homeostasis assessment model of insulin resistance; ∧ of area under the curve of glucose; °°hepatic insulin resistance index; ns: not significant.
